December 6, 2021
Mitsubishi Tanabe Pharma and Janssen Pharmaceutical K.K. said on December 3 that the companies have entered into a copromotion agreement for the vesicular monoamine transporter 2 (VMAT2) inhibitor valbenazine, which is currently under development in Japan by Mitsubishi Tanabe for...read more